After surgical resection of the liver cancer, adjuvant therapy may prevent recurrence.

Published Date: 19 Apr 2023

The findings showed that after surgical resection or ablation, patients with hepatocellular carcinoma (HCC) who received adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) had a higher rate of recurrence-free survival.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot